The 10mg Catastrophe

Presentation

The patient presented with nephrotic syndrome and began standard guideline-directed therapy, including atorvastatin 10mg daily for hypercholesterolemia. Baseline renal function was compromised but stable (CKD Stage 2). No genetic testing was performed prior to initiation.

Key Finding

By day 4, the patient developed severe myalgias. Laboratory tests revealed a Creatine Kinase (CK) level of 11,821 IU/L — an extreme myotoxic response at the absolute minimum statin dose. South Asian populations frequently carry genetic variants in SLCO1B1 and CYP3A4 genes that dramatically reduce hepatic uptake and metabolism of statins.

Intervention & Outcome

The statin was immediately discontinued. The patient required aggressive IV hydration to prevent progression to acute renal failure. Following statin cessation, CK levels normalized over two weeks. Pharmacogenomic testing was strongly recommended but was not yet standard protocol in this setting.

First Principles

Statins enter hepatocytes via the SLCO1B1 transporter. The SLCO1B1*5 variant (c.521T>C) is carried by ~15-20% of South Asians vs ~5-10% of Europeans. Each copy reduces transporter function ~50%. A homozygous carrier on 10mg has effective systemic exposure equivalent to 40mg in a wild-type European. Add CKD-impaired clearance and reduced muscle mass, and you have catastrophic myocyte exposure at 'minimum' doses.